DNA NYSE Week ended 31 Jul 2026

Weekly Investor Report

Ginkgo Bioworks Holdings · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 8.09 USD
9.9% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -3.2% below the Trend Line and sits at 22.3% of its 52-week range. The latest completed week returned 9.9%, after a -22.2% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 52/100 conviction, while the latest news-sentiment score is 47/100. Near-term considerations: volume confirmation is below normal; earnings are due in 4d.

Setup score 17 out of 100
Latest Close 8.09 USD 31 Jul 2026
1W Return 9.9% latest completed week
4W Return -22.2% short-term follow-through
12W Return -9.4% quarterly tape
Trend Breadth 30.8% 16 of 52 weeks active
Volume Ratio 0.6x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 9.9% Latest completed week; four-week move -22.2%. Indicator stack 17/42 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 42.30% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 52/100 conviction; expected move 23.8%. News sentiment 47/100 71 relevant articles in the latest sentiment read. Event risk 4d Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -3.2% below the Trend Line and sits at 22.3% of its 52-week range. The latest completed week returned 9.9%, after a -22.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2212-week average 0.14

12-week confirmation

Trend active3/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure11/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.22Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -22.2% over four weeks, -9.4% over 12 weeks, and -33.6% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W9.9%
4W-22.2%
12W-9.4%
26W-9.8%
52W-33.6%
Active trend streak0 weeks
Active weeks in one year16
Trend breadth30.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.01Latest activity-pressure read.
Pressure change-101.1%Four-week change in activity pressure.
Leadership-22.05Latest relative-leadership reading.
RS change-507.5%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength7/100Blend of value, momentum, and quality. Underlying universe rank 94; rank 1 is best.
Value35/100Relative valuation strength. Underlying universe rank 66; rank 1 is best.
Quality9/100Profitability and accounting quality. Underlying universe rank 92; rank 1 is best.
Momentum9/100Medium-term price momentum. Underlying universe rank 92; rank 1 is best.
Growth12/100Revenue and earnings growth. Underlying universe rank 89; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
3.4x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-18.9%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
75.0%
Gross profit retained from each unit of revenue.
Operating margin
-212.4%
Operating profit retained from revenue.
Free-cash-flow margin
-99.8%
Free cash flow generated from revenue.
Return on invested capital
-31.7%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-40.5%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-4.0%
Net share repurchases relative to market value.
Shareholder yield
-4.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-1.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

DNA shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.04, expected move of 23.8%, and Sharemaestro trend signal inactive.

Conviction52/100
Expected move23.8%
Put/call volume0.04
Pressure100
Speculation3
Volatility96
Trend agreement0
Open options detail
Insider activity10 / 9

10 acquisitions and 9 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment47/100

Weighted news tone is neutral across 71 relevant articles.

5 positive · 56 neutral · 10 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move23.8%Nearest-chain priced movement where available.
52-week drawdown-54.0%Distance below the 52-week high.
13-week volatility10.7%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+24.5%Week of 17 Apr.
Worst week-26.8%Week of 27 Feb.
Latest week+9.9%Week of 31 Jul.

Shape of recent returns

Strong gains10
Modest gains1
Flat weeks0
Modest losses4
Sharp losses11
Recent vol10.7%13-week weekly-return volatility.
Base vol12.5%52-week weekly-return volatility.
Up/down split26/26Count of positive and negative weeks in the 52-week window.
Average skew9.5% / -9.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape20/100

Trend, activity pressure, participation, and risk combine to a 20/100 tape read.

 Indicator analysis38/100

Latest 12-week confirmation: trend 3/12, activity pressure 11/12, relative leadership 0/12.

Activity pressure 0.22; No reversal markers Next-Week ExpectancyNegative 42.30%

Next-week expectancy is negative with a 42.30% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors13/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 81; Small Cap Core rank 71 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options36/100

DNA shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.04, expected move of 23.8%, and Sharemaestro trend signal inactive.

Volatility · Volatility expansion watch · Expected move 23.8% Sentiment47/100

Weighted news tone is neutral across 71 relevant articles.

Ginkgo Bioworks (NYSE: DNA) plans Q2 2026 results presentation and Q&A Insiders10 / 9

10 acquisitions and 9 disposals in the latest 180-day insider tape.

 Earnings4d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20268.09 USD9.9%8.36 USD22.19 USD-0.01-22.053.4MOff
24 Jul 20267.36 USD-7.0%8.38 USD22.66 USD0.37-29.193.7MOff
17 Jul 20267.91 USD-13.0%8.42 USD23.24 USD0.83-25.594.4MOn
10 Jul 20269.09 USD-12.6%8.42 USD23.80 USD1.02-16.455.9MOn
3 Jul 202610.40 USD1.5%8.43 USD24.27 USD0.96-3.635.0MOn
26 Jun 202610.25 USD11.8%8.39 USD24.65 USD0.99-3.817.0MOff
19 Jun 20269.17 USD16.2%8.36 USD25.06 USD0.88-16.154.1MOff
12 Jun 20267.89 USD-4.0%8.33 USD25.44 USD0.76-27.404.6MOff
5 Jun 20268.22 USD-12.3%8.33 USD25.88 USD0.68-24.3911.0MOff
29 May 20269.37 USD11.4%8.36 USD26.30 USD0.65-16.154.3MOff
22 May 20268.41 USD9.1%8.48 USD26.65 USD0.65-23.604.1MOff
15 May 20267.71 USD-13.7%8.65 USD26.99 USD0.49-29.436.3MOff
8 May 20268.93 USD-7.9%8.83 USD27.27 USD0.44-18.429.8MOff
1 May 20269.70 USD23.3%8.99 USD27.53 USD-0.09-9.516.3MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.